Vor Bio Announces Data Phase 3 Trial Of Telitacicept By Its RemeGen Partner Demonstrates Over 95% Participants Achieved At Least 5-Point MG-ADL Improvement Over 48 Weeks

Vor Bio (Nasdaq: VOR) announced a post hoc analysis from a Phase 3 trial conducted by its partner RemeGen, showing that over 95% of participants with generalized myasthenia gravis achieved at least a 5-point improvement on the MG-ADL scale over 48 weeks. The findings were presented at the MGFA Scientific Session during the 2026 AANEM Annual Meeting in Orlando, Florida.